A Healthcare Technology Company

Shaping the future of noninvasive diagnosis with artificial intelligence.

Uniquely Positioned among Noninvasive technologies

A combination of broadly available biomarkers and neural network-based AI provides a diagnostics accuracy equivalent to biopsy​.

Fibronostics patent technology

Patented Technology

CPT Code: 0166U

Fibronostics CE mark

CE mark

(Conformité Européenne)

Fibronostics patent technology

AI Technology-based

Complete Liver Diagnosis

LIVERFASt™ – from Early Stage to Late Stage
for NAFLD, NASH Cirrhosis that provides prognosis for liver-related hard outcomes including HCC

Fibronostics Screening


Risk stratification among large patient populations allows for better management leading to cost reductions.

Fibronostics Diagnosis


Noninvasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

Fibronostics Monitoring


Regular surveillance with easily repeatable noninvasive diagnostics enables optimized disease management.

Noninvasive solutions for diagnosis, screening and monitoring.